Published in BMC Infect Dis on February 01, 2016
Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens. J Clin Microbiol (1983) 10.49
Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med (2011) 7.13
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med (2003) 6.07
Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med (2011) 5.31
Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis (2005) 4.57
Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet (2004) 4.21
Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis (2011) 2.70
Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am J Trop Med Hyg (2006) 2.05
Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis (2006) 1.94
Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb) (2012) 1.87
Risk factors for death among tuberculosis cases: analysis of European surveillance data. Eur Respir J (2008) 1.52
Predictors and mortality associated with treatment default in pulmonary tuberculosis. Int J Tuberc Lung Dis (2010) 1.44
Mortality and associated risk factors in a cohort of tuberculosis patients treated under DOTS programme in Addis Ababa, Ethiopia. BMC Infect Dis (2011) 1.35
A web-based laboratory information system to improve quality of care of tuberculosis patients in Peru: functional requirements, implementation and usage statistics. BMC Med Inform Decis Mak (2007) 1.26
Factors associated with deaths among pulmonary tuberculosis patients: a case-control study with secondary data. J Epidemiol Community Health (2008) 1.21
HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. Int J Tuberc Lung Dis (2012) 1.19
Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005-2008. Emerg Infect Dis (2011) 1.19
Scale-up of multidrug-resistant tuberculosis laboratory services, Peru. Emerg Infect Dis (2008) 1.17
Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. Clin Infect Dis (2014) 1.11
Programmatic implementation of rapid DST for Mycobacterium tuberculosis in Peru. Int J Tuberc Lung Dis (2008) 1.02
Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J Acquir Immune Defic Syndr (2012) 0.99
[Factors associated with survival of patients with tuberculosis in Lima, Peru]. Rev Chilena Infectol (2008) 0.98
Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors. PLoS One (2015) 0.90
Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis (2012) 0.81
Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease. PLoS One (2013) 0.77